Bayesian Methods in Phase III Trials
- 1 July 1991
- journal article
- Published by Springer Science and Business Media LLC in Drug Information Journal
- Vol. 25 (3), 345-368
- https://doi.org/10.1177/009286159102500306
Abstract
This paper describes a Bayesian approach to the design and analysis of clinical trials, with special reference to Phase III drug trials. The focus is on two rather general areas that are important in clinical trials: (1) monitoring trials with the possibility of changing the trial's design, and (2) combining various sources of information concerning the effect of the drug. Topics covered include survival analysis, analysis of trials in which the patients have different prognoses, multicenter trials and meta-analysis.Keywords
This publication has 13 references indexed in Scilit:
- Population ModelsPublished by Informa UK Limited ,2016
- Bayesian MetaanalysisPublished by Informa UK Limited ,2016
- The Relevance of Stopping Rules in Statistical InferencePublished by Springer Science and Business Media LLC ,1988
- Interim Analysis in Clinical Trials: The Role of the Likelihood PrincipleThe American Statistician, 1987
- Bandit problemsPublished by Springer Science and Business Media LLC ,1985
- Repeated confidence intervals for group sequential clinical trialsControlled Clinical Trials, 1984
- On choosing the number of interim analyses in clinical trialsStatistics in Medicine, 1982
- Group sequential methods in the design and analysis of clinical trialsBiometrika, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976
- The Effect of 6-Mercaptopurine on the Duration of Steroid-induced Remissions in Acute Leukemia: A Model for Evaluation of Other Potentially Useful TherapyBlood, 1963